A drug for the treatment of Hunter syndrome in an innovative form of administration, Hunterase Neuro, has been approved in the Russian Federation. The holder of the registration certificate is the Nanolek company, which has exclusive rights to distribute and promote the drug.

Hunterase Neuro (idursulfase beta ICV) is used for enzyme replacement therapy for mucopolysaccharidosis type II, or Hunter syndrome. Unlike Hunterase, the new drug is administered not intravenously, but intracerebroventricularly, that is, directly into the ventricles of the brain, using the ventricular reservoir. This method allows the drug to be administered bypassing the blood-brain barrier. During the period of use of the drug in real clinical practice in Japan, not a single case of infectious complications from the central nervous system was recorded, which is due to the short administration time, which takes no more than two minutes. The debut of Hunterase Neuro in Russia became possible thanks to the cooperation of Nanolek with the South Korean biopharmaceutical company GC Biopharma, which has been going on for nine years. In 2018, Hunterase, developed by South Korean biotechnologists, appeared in the Nanolek portfolio.

Nato Vashakmadze, Head of the Department of Orphan Diseases and Prevention of Disabling Diseases, Russian Scientific Center for Surgery named after Academician B.V. Petrovsky, pediatric cardiologist:

- Hunterase Neuro is an innovative drug intended for the treatment of patients with Hunter syndrome. Intracerebroventricular drug delivery is a therapy that is aimed at correcting the neurological manifestations of the disease.

Dmitry Reshchikov, neurosurgeon at the Russian Children's Clinical Hospital of the Russian National Research Medical University named after. N.I. Pirogov Ministry of Health of Russia, physician of the superior expert category:

- This drug is developed for the treatment of Hunter syndrome, taking into account its point of application. Hunterase Neuro is injected directly into the ventricles of the brain, thus influencing the central nervous system, which was impossible until recently.

For reference: Hunter syndrome, or mucopolysaccharidosis type II, is a rare genetic disease caused by a deficiency of the enzyme iduronate-2-sulfatase, which leads to the accumulation of glycosaminoglycans in the body and causes damage to various organs and tissues.